[시장보고서]세계의 3D 세포배양 시장 : 제품별, 용도별, 최종 사용자별, 지역별 예측(-2030년)

세계의 3D 세포배양 시장 : 제품별, 용도별, 최종 사용자별, 지역별 예측(-2030년)

3D Cell Culture Market by Product (Scaffolds, Scaffold-free, Microfluidics, Bioprinted), Application, End User, Region - Global Forecast to 2030

상품코드 : 1840918 해당 상품은 즉시 배송 가능합니다

리서치사 : MarketsandMarkets

발행일 : 2025년 10월

페이지 정보 : 영문 323 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,950

￦ 7,159,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650

￦ 9,617,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150

￦ 11,787,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,463,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 3D 세포배양 시장 규모는 2024년 11억 8,000만 달러에서 2030년까지 22억 6,000만 달러에 이를 것으로 예상되며, 예측 기간에 CAGR은 11.7%를 나타낼 것으로 전망됩니다.

조사 범위
조사 대상 연도	2024-2030년
기준 연도	2024년
예측 기간	2025-2030년
단위	10억 달러
부문	제품, 용도, 최종 사용자
대상 지역	북미, 아시아태평양, 유럽, 라틴아메리카, 중동 및 아프리카

3D 세포배양 채용 증가와 3D 세포배양 연구에 대한 자금 제공 증가 등의 요인이 시장 성장을 가속하고 있습니다.

제품 시장에서 스캐폴드 기반 3D 세포배양 부문은 가장 높은 시장 점유율을 차지했습니다.

스캐폴드 기반 3D 세포배양 부문은 2024년에 가장 큰 점유율을 차지했습니다. 하이드로겔/ECM 아날로그가 부문 성장의 주인으로 부상하고 있습니다. 하이드로겔에 대한 수요가 증가함에 따라 시장에서 신제품 개발과 상시에 대한 주요 시장 기업의 관심이 높아지고 있습니다. 또한, 하이드로겔은 생체적합성이 있고 독성이 없기 때문에 연구 및 의약품 개발에 이상적입니다.

용도 시장에서는 암·줄기세포 연구 부문이 2024년에 가장 큰 점유율을 차지했습니다.

암·줄기세포 연구 부문이 2024년 최대 시장 점유율을 차지했습니다. 암 유병률 증가, 관민 부문에 의한 암 연구에 중요한 자금 제공 전략이 이 응용 분야의 주요 성장 촉진요인입니다.

아시아태평양이 가장 급성장하는 지역 시장이 될 가능성이 높습니다.

이 시장 성장은 유리한 규제 지침의 존재, 세포배양 기반 백신 생산에 대한 정부의 지원, 낮은 제조 비용, 세계 시장 기업의 신흥 아시아 국가에 대한 관심 증가로 인한 것입니다. 아시아태평양에서는 항체 및 단백질 기반 의약품과 같은 생물학적 제제 시장도 상승 기조에 있습니다. 바이오테크놀러지 기반 의약품은 연구 증가와 이러한 의약품에 대한 정부의 자금 제공 증가로 연구 산업의 주요 성장 촉진요인 중 하나가 될 것으로 예측됩니다. 세계 제약기업은 아시아로 제조거점을 옮겨 활발한 시장을 개발하고 제조비용을 낮추기 위해 아시아로 진출을 추진하고 있습니다.

이 보고서는 세계의 3D 세포배양 시장에 대한 조사 분석을 통해 주요 성장 촉진요인과 억제요인, 경쟁 구도, 미래 동향 등의 정보를 제공합니다.

서론
시장 역학
- 성장 촉진요인
- 성장 억제요인
- 기회
- 과제
기술 분석
- 핵심 기술
- 보완 기술
- 인접 기술
무역 분석
- 수입 데이터
- 수출 데이터
규제 상황
- 규제 틀
- 규제기관, 정부기관, 기타 조직
Porter's Five Forces 분석
3D 세포배양 시장에 대한 AI/생성형 AI의 영향
- 서론
- 3D 세포배양 용도에 있어서 AI 시장의 장래성
- AI 이용 사례
- AI를 도입하고 있는 주요 기업
- 3D 세포배양 생태계에서 생성형 AI의 미래
3D 세포배양 시장에 대한 미국 관세의 영향(2025년)
- 서론
- 주요 관세율
- 가격의 영향 분석
- 국가/지역에 미치는 영향
- 최종 이용 산업에 대한 영향

제6장 산업 동향

가격 설정 분석
- 평균 판매 가격 동향 : 주요 기업별
- 평균 판매 가격 동향 : 지역별
특허 분석
- 조사 방법
- 출원 특허수
- 주요 특허 목록
주요 컨퍼런스 및 이벤트(2025-2026년)
투자 및 자금조달 시나리오
밸류체인 분석
생태계 분석
주요 이해관계자와 구매 기준
고객사업에 영향을 주는 동향/파괴적 변화

제7장 3D 세포배양 시장 : 유형별

서론
스캐폴드 기반 3D 세포배양
스캐폴드 프리 3D 세포배양
마이크로플루이딕스 기반 3D 세포배양
자기 및 바이오프린팅 3D 세포배양

제8장 3D 세포배양 시장 : 용도별

서론
암 및 줄기세포 연구
신약 개발 및 독성학 시험
조직공학 및 재생의료
3D 세포배양 시장 : 모델 유형별

제9장 3D 세포배양 시장 : 최종 사용자별

서론
제약 및 바이오테크놀러지 기업
연구기관
화장품 산업
기타 최종 사용자

제10장 3D 세포배양 시장 : 지역별

서론
북미
- 북미의 거시경제 전망
- 미국
- 캐나다
유럽
- 유럽의 거시 경제 전망
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
아시아태평양
- 아시아태평양의 거시 경제 전망
- 중국
- 일본
- 인도
- 한국
- 호주
- 기타 아시아태평양
라틴아메리카
- 라틴아메리카의 거시 경제 전망
- 브라질
- 멕시코
- 기타 라틴아메리카
중동
- 중동의 거시 경제 전망
- GCC 국가
- 기타 중동
아프리카

제11장 경쟁 구도

서론
주요 진입기업의 전략/강점
수익 분석(2020-2024년)
시장 점유율 분석(2024년)
기업 평가 및 재무 지표
브랜드/제품 비교
기업 평가 매트릭스 : 주요 기업(2024년)
기업 평가 매트릭스 : 스타트업/중소기업(2024년)
경쟁 시나리오

제12장 기업 프로파일

주요 기업
- THERMO FISHER SCIENTIFIC INC.
- MERCK KGAA
- CORNING INCORPORATED
- LONZA
- AVANTOR, INC.
- TECAN TRADING AG
- REPROCELL INC.
- 3D BIOTEK LLC
- EMULATE, INC.
- SYNTHECON, INCORPORATED
- INSPHERO
- KIRKSTALL LTD.
- GREINER BIO-ONE INTERNATIONAL GMBH
- PROMOCELL GMBH
- UPM
기타 기업
- CN BIO INNOVATIONS LTD.
- TISSUSE GMBH
- LENA BIOSCIENCES
- CELLENDES GMBH
- ADVANCED BIOMATRIX, INC.(PART OF BICO)
- SYNVIVO, INC.
- AMS BIOTECHNOLOGY(EUROPE) LTD
- MIMETAS BV
- S-BIO, VAUPELL HOLDINGS INC.
- NANOFIBER SOLUTIONS

제13장 부록

KTH

영문 목차

영문목차

The global 3D cell culture market is projected to reach USD 2.26 billion by 2030 from USD 1.18 billion in 2024, at a CAGR of 11.7% during the forecast period.

Scope of the Report
Years Considered for the Study	2024-2030
Base Year	2024
Forecast Period	2025-2030
Units Considered	Value (USD billion)
Segments	Product, Application, End User
Regions covered	North America, Asia Pacific, Europe, Latin America, Middle East & Africa

Factors such as increased adoption of 3D cell culture and a rise in funding for 3D cell culture research drive market growth.

The scaffold-based 3D cell culture segment accounted for the highest market share in the product market.

Based on the product, the 3D cell culture market is segmented into scaffold-based 3D cell cultures, scaffold-free 3D cell cultures, microfluidics-based 3D cell cultures, and magnetic & bioprinted 3D cell cultures. The scaffold-based 3D cell cultures segment accounted for the largest share in 2024. Hydrogels/ECM analogs have emerged as the key contributor to segment growth. Increased demand for hydrogels is raising the focus of key market players on the development and launch of new products in the market. It is also biocompatible and non-toxic, making it ideal for use in research and drug development.

The cancer and stem cell research segment accounted for the largest share of the application market in 2024.

Based on the application, the market is segmented into cancer & stem cell research, drug discovery & toxicology testing, and tissue engineering & regenerative medicine. Cancer & stem cell segment research accounted for the largest market share in 2024. The increasing prevalence of cancer and significant funding initiatives for cancer research from the government and the private sector are major factors driving the growth of this application segment.

The Asia Pacific region is likely to be the fastest-growing regional market.

The 3D cell culture market is segmented into Europe, Asia Pacific, North America, Latin America, and the Middle East & Africa. The Asia Pacific market is expected to be the fastest-growing regional segment during the forecast period. Growth in this market is attributed to the presence of favorable regulatory guidelines, government support for cell culture-based vaccine production, low manufacturing costs, and the growing focus of global market players on emerging Asian countries. The markets for biologics such as antibodies and protein-based drugs are also on the rise in the Asia Pacific region. Biotechnology-based drugs are anticipated to be one of the key drivers for the research industry due to increased research and government funds provided for these drugs. Global pharmaceutical firms are increasingly moving to Asia to tap into its thriving market and lower their production costs by shifting manufacturing to the region.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Tier 1- 25%, Tier 2- 35%, and Tier 3- 40%
By Designation: C-level Executives- 55%, Directors- 20%, and Others- 25%
By Region: North America- 45%, Europe- 20%, the Asia Pacific- 20%, Latin America- 10%, the Middle East- 3%, and Africa- 2%

The top players in the global 3D cell culture market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Corning Incorporated (US), Lonza (Switzerland), Tecan Trading AG (Switzerland), Avantor, REPROCELL Inc. (Japan), 3D Biotek LLC. (US), S-BIO, Vaupell Holdings Inc. (US), Advanced BioMatrix Inc. (US), UPM Biomedicals (Finland), SYNTHECON, INCORPORATED (US), Emulate, Inc. (US), CN Bio Innovations Ltd. (UK), Kirkstall Ltd. (UK), Lena Biosciences (US), TissUse GmbH (Germany), Cellendes GmbH (Germany), Greiner Bio-one International GmbH (Germany), AMSBIO (UK), MIMETAS B.V.(Netherlands), and Promocell GmbH (Germany).

Research Coverage

This research report categorizes the 3D cell culture market by product (scaffold-based 3D cell cultures, scaffold-free 3D cell cultures, microfluidics-based 3D cell cultures, and magnetic & bioprinted 3D cell cultures), application (cancer & stem cell research, drug discovery & toxicology testing, and tissue engineering & regenerative medicine), end user (pharmaceutical & biotechnology companies, research institutes, cosmetics industry, and other end users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the 3D cell culture market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, and acquisitions, and recent developments associated with the 3D cell culture market. This report covers a competitive analysis of top players and upcoming startups in the 3D cell culture market ecosystem.

The report's scope covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the 3D cell culture market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product launches, acquisitions, and recent developments associated with the 3D cell culture market. This report covers the competitive analysis of upcoming startups in the 3D cell culture market ecosystem.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall 3D cell culture market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (high focus on developing alternatives to animal testing, increasing adoption of personalized medicine, increased government support and funding, rising academia-research collaborations), restraints (high cost of implementing 3D cell culture technologies, lack of widely accepted or single standardization in 3D cell culture), opportunities (emergence of microfluidic based 3D cell culture), and challenges (lack of consistency in 3D cell culture products, high dependency on plastic waste disposals and consumables) influencing the growth of 3D cell culture market.
Product Development/Innovation: Detailed insights on newly launched products of the 3D cell culture market
Market Development: Comprehensive information about lucrative markets - the report analyses the 3D cell culture market across varied regions.
Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the 3D cell culture market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Corning Incorporated (US), Lonza (Switzerland), and Avantor Inc. (US), among others

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
- 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF STRATEGIC CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
  - 2.1.1.1 Key sources of secondary data
  - 2.1.1.2 Key objectives of secondary research
- 2.1.2 PRIMARY DATA
  - 2.1.2.1 Breakdown of primaries
  - 2.1.2.2 Key objectives of primary research
2.2 MARKET SIZE ESTIMATION
- 2.2.1 GLOBAL MARKET SIZE ESTIMATION
  - 2.2.1.1 Revenue share analysis (bottom-up approach)
  - 2.2.1.2 Secondary data
  - 2.2.1.3 Primary interviews and MnM repository analysis
- 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
- 2.2.3 SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)
2.3 GROWTH RATE PROJECTION
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

3.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS
3.3 DISRUPTIVE TRENDS SHAPING MARKET
3.4 HIGH-GROWTH SEGMENTS AND EMERGING FRONTIERS
3.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

4 PREMIUM INSIGHTS

4.1 UNMET NEEDS AND WHITE SPACES
4.2 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
4.3 EMERGING BUSINESS MODELS AND ECOSYSTEM SHIFTS
4.4 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
4.5 VC/PRIVATE EQUITY INVESTMENT TRENDS AND STARTUP LANDSCAPE
4.6 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
  - 5.2.1.1 High focus on developing alternatives to animal testing
  - 5.2.1.2 Growing shift toward personalized medicine
  - 5.2.1.3 Integration of microphysiological systems and organ-on-chip platforms
- 5.2.2 RESTRAINTS
  - 5.2.2.1 High costs of implementing 3D cell culture technologies
  - 5.2.2.2 Absence of widely accepted or unified standards for experimental protocols
- 5.2.3 OPPORTUNITIES
  - 5.2.3.1 High growth opportunities and booming biopharmaceutical sector in emerging economies
- 5.2.4 CHALLENGES
  - 5.2.4.1 Lack of consistency in scaffold-based 3D cell culture products
  - 5.2.4.2 High dependence on plastic waste disposals and consumables
5.3 TECHNOLOGY ANALYSIS
- 5.3.1 KEY TECHNOLOGIES
  - 5.3.1.1 Microfluidics
  - 5.3.1.2 Bioprinting
  - 5.3.1.3 Organ-on-chip
- 5.3.2 COMPLEMENTARY TECHNOLOGIES
  - 5.3.2.1 High-content imaging and automated microscopy
  - 5.3.2.2 High-throughput screening platforms
- 5.3.3 ADJACENT TECHNOLOGIES
  - 5.3.3.1 Magnetic levitation
  - 5.3.3.2 Microfabrication
5.4 TRADE ANALYSIS
- 5.4.1 IMPORT DATA
- 5.4.2 EXPORT DATA
5.5 REGULATORY LANDSCAPE
- 5.5.1 REGULATORY FRAMEWORK
  - 5.5.1.1 North America
  - 5.5.1.2 Europe
  - 5.5.1.3 Asia Pacific
  - 5.5.1.4 Latin America
  - 5.5.1.5 Middle East & Africa
- 5.5.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.6 PORTER'S FIVE FORCES ANALYSIS
- 5.6.1 BARGAINING POWER OF SUPPLIERS
- 5.6.2 BARGAINING POWER OF BUYERS
- 5.6.3 THREAT OF NEW ENTRANTS
- 5.6.4 THREAT OF SUBSTITUTES
- 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
5.7 IMPACT OF AI/GENERATIVE AI ON 3D CELL CULTURE MARKET
- 5.7.1 INTRODUCTION
- 5.7.2 MARKET POTENTIAL OF AI IN 3D CELL CULTURE APPLICATIONS
- 5.7.3 AI USE CASES
- 5.7.4 KEY COMPANIES IMPLEMENTING AI
- 5.7.5 FUTURE OF GENERATIVE AI IN 3D CELL CULTURE ECOSYSTEM
5.8 IMPACT OF 2025 US TARIFF ON 3D CELL CULTURE MARKET
- 5.8.1 INTRODUCTION
- 5.8.2 KEY TARIFF RATES
- 5.8.3 PRICE IMPACT ANALYSIS
- 5.8.4 IMPACT ON COUNTRY/REGION
  - 5.8.4.1 US
  - 5.8.4.2 Europe
  - 5.8.4.3 Asia Pacific
- 5.8.5 IMPACT ON END-USE INDUSTRIES
  - 5.8.5.1 Pharmaceutical and biotech companies
  - 5.8.5.2 Hospitals and diagnostic laboratories
  - 5.8.5.3 Academic and research institutes
  - 5.8.5.4 Contract research organizations & contract development and manufacturing organizations

6 INDUSTRY TRENDS

6.1 PRICING ANALYSIS
- 6.1.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
- 6.1.2 AVERAGE SELLING PRICE TREND, BY REGION
6.2 PATENT ANALYSIS
- 6.2.1 METHODOLOGY
- 6.2.2 NUMBER OF PATENTS FILED
- 6.2.3 LIST OF KEY PATENTS
6.3 KEY CONFERENCES AND EVENTS, 2025-2026
6.4 INVESTMENT AND FUNDING SCENARIO
6.5 VALUE CHAIN ANALYSIS
6.6 ECOSYSTEM ANALYSIS
6.7 KEY STAKEHOLDERS AND BUYING CRITERIA
- 6.7.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 6.7.2 KEY BUYING CRITERIA
6.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS

7 3D CELL CULTURE MARKET, BY TYPE

7.1 INTRODUCTION
7.2 SCAFFOLD-BASED 3D CELL CULTURES
- 7.2.1 HYDROGELS/ECM ANALOGS
  - 7.2.1.1 Hydrogels/ECM analogs to dominate scaffold-based 3D cell culture market during forecast period
- 7.2.2 SOLID SCAFFOLDS
  - 7.2.2.1 Growing adoption of solid scaffolds in regenerative medicine and preclinical in vitro testing to boost market
- 7.2.3 MICROPATTERNED SURFACES
  - 7.2.3.1 Ability of micropatterned surfaces to enhance expression of enzyme levels and drug reactivity to drive growth
7.3 SCAFFOLD-FREE 3D CELL CULTURES
- 7.3.1 LOW-ATTACHMENT PLATES
  - 7.3.1.1 Low-attachment plates to grow at highest rate in scaffold-free 3D cell cultures market
- 7.3.2 HANGING DROP PLATES
  - 7.3.2.1 Growing use of hanging drop plates in stem cell differentiation and cytotoxicity research to propel growth
- 7.3.3 3D BIOREACTORS
  - 7.3.3.1 Wide usage of 3D bioreactors in mass production of cells to support market growth
7.4 MICROFLUIDICS-BASED 3D CELL CULTURES
- 7.4.1 MICROFLUIDICS-BASED 3D CELL CULTURES TO GROW AT HIGHEST RATE IN 3D CELL CULTURE MARKET DURING FORECAST PERIOD
7.5 MAGNETIC & BIOPRINTED 3D CELL CULTURES
- 7.5.1 GROWING USE OF BIOPRINTING TECHNOLOGIES IN CANCER MODEL CREATION TO BOOST MARKET

8 3D CELL CULTURE MARKET, BY APPLICATION

8.1 INTRODUCTION
8.2 CANCER & STEM CELL RESEARCH
- 8.2.1 INCREASING DEMAND FOR PATIENT-DERIVED, AUTOMATED 3D ORGANOID SYSTEMS TO PROPEL MARKET
8.3 DRUG DISCOVERY & TOXICOLOGY TESTING
- 8.3.1 REGULATORY DEMAND AND TECHNOLOGICAL MATURATION OF PREDICTIVE 3D TOXICOLOGY MODELS TO DRIVE MARKET GROWTH
8.4 TISSUE ENGINEERING & REGENERATIVE MEDICINE
- 8.4.1 ADVANCEMENTS IN BIOMATERIAL INNOVATION AND SCAFFOLD CUSTOMIZATION TO BOOST MARKET
8.5 3D CELL CULTURE MARKET, BY MODEL TYPE

9 3D CELL CULTURE MARKET, BY END USER

9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 9.2.1 GROWING INTEGRATION OF 3D MODELS BY PHARMA AND BIOTECH COMPANIES TO DRIVE MARKET GROWTH
9.3 RESEARCH INSTITUTES
- 9.3.1 RESEARCH GRANTS FROM GOVERNMENTAL AND NON-GOVERNMENTAL ORGANIZATIONS TO AUGMENT MARKET
9.4 COSMETICS INDUSTRY
- 9.4.1 GROWING FOCUS ON DEVELOPING ALTERNATIVES FOR ANIMAL TESTING TO FUEL MARKET
9.5 OTHER END USERS

10 3D CELL CULTURE MARKET, BY REGION

10.1 INTRODUCTION
10.2 NORTH AMERICA
- 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 10.2.2 US
  - 10.2.2.1 Product launches and capacity expansions to drive market growth
- 10.2.3 CANADA
  - 10.2.3.1 Advancements in tissue therapeutics and regenerative medicine to boost market
10.3 EUROPE
- 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 10.3.2 GERMANY
  - 10.3.2.1 Strategic acquisitions to fuel market growth
- 10.3.3 UK
  - 10.3.3.1 Growing government funding and initiatives to propel market growth
- 10.3.4 FRANCE
  - 10.3.4.1 Strategic collaborations to propel market growth
- 10.3.5 ITALY
  - 10.3.5.1 Strong government support to enhance R&D activities
- 10.3.6 SPAIN
  - 10.3.6.1 Strategic R&D investments and collaborative frameworks to drive market
- 10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
- 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 10.4.2 CHINA
  - 10.4.2.1 Rising pharmaceutical R&D and investments to drive market growth
- 10.4.3 JAPAN
  - 10.4.3.1 Strategic collaborations and technological advancements to augment market
- 10.4.4 INDIA
  - 10.4.4.1 Strategic collaborations and infrastructure development to support market
- 10.4.5 SOUTH KOREA
  - 10.4.5.1 Strategic investments and collaborations to propel market growth
- 10.4.6 AUSTRALIA
  - 10.4.6.1 Advancements in 3D cell culture technologies to propel market
- 10.4.7 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
- 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 10.5.2 BRAZIL
  - 10.5.2.1 Rising prevalence of cancer and therapeutic development to support market
- 10.5.3 MEXICO
  - 10.5.3.1 Growth in biopharmaceutical market to spur 3D cell culture demand
- 10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST
- 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
- 10.6.2 GCC COUNTRIES
  - 10.6.2.1 Saudi Arabia
    - 10.6.2.1.1 Strategic healthcare initiatives to drive market
  - 10.6.2.2 UAE
    - 10.6.2.2.1 Developments in healthcare infrastructure and growing government initiatives to drive market
  - 10.6.2.3 Rest of GCC Countries
- 10.6.3 REST OF MIDDLE EAST
10.7 AFRICA
- 10.7.1 STRATEGIC COLLABORATIONS AND HEALTH INITIATIVES TO FUEL MARKET GROWTH
- 10.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN 3D CELL CULTURE MARKET
11.3 REVENUE ANALYSIS, 2020-2024
11.4 MARKET SHARE ANALYSIS, 2024
11.5 COMPANY VALUATION AND FINANCIAL METRICS
- 11.5.1 COMPANY VALUATION
- 11.5.2 FINANCIAL METRICS
11.6 BRAND/PRODUCT COMPARISON
11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
- 11.7.1 STARS
- 11.7.2 EMERGING LEADERS
- 11.7.3 PERVASIVE PLAYERS
- 11.7.4 PARTICIPANTS
- 11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
  - 11.7.5.1 Company footprint
  - 11.7.5.2 Region footprint
  - 11.7.5.3 Product footprint
  - 11.7.5.4 Application footprint
  - 11.7.5.5 End-user footprint
11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 11.8.1 PROGRESSIVE COMPANIES
- 11.8.2 RESPONSIVE COMPANIES
- 11.8.3 DYNAMIC COMPANIES
- 11.8.4 STARTING BLOCKS
- 11.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
  - 11.8.5.1 Detailed list of key startups/SMEs
  - 11.8.5.2 Competitive benchmarking of startups/SMEs
11.9 COMPETITIVE SCENARIO
- 11.9.1 PRODUCT LAUNCHES
- 11.9.2 DEALS
- 11.9.3 EXPANSIONS
- 11.9.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

12.1 KEY PLAYERS
- 12.1.1 THERMO FISHER SCIENTIFIC INC.
  - 12.1.1.1 Business overview
  - 12.1.1.2 Products offered
  - 12.1.1.3 Recent developments
    - 12.1.1.3.1 Product launches
    - 12.1.1.3.2 Deals
    - 12.1.1.3.3 Expansions
  - 12.1.1.4 MnM view
    - 12.1.1.4.1 Key strengths
    - 12.1.1.4.2 Strategic choices
    - 12.1.1.4.3 Weaknesses and competitive threats
- 12.1.2 MERCK KGAA
  - 12.1.2.1 Business overview
  - 12.1.2.2 Products offered
  - 12.1.2.3 Recent developments
    - 12.1.2.3.1 Deals
    - 12.1.2.3.2 Expansions
  - 12.1.2.4 MnM view
    - 12.1.2.4.1 Key strengths
    - 12.1.2.4.2 Strategic choices
    - 12.1.2.4.3 Weaknesses and competitive threats
- 12.1.3 CORNING INCORPORATED
  - 12.1.3.1 Business overview
  - 12.1.3.2 Products offered
  - 12.1.3.3 Recent developments
    - 12.1.3.3.1 Product launches
  - 12.1.3.4 MnM view
    - 12.1.3.4.1 Key strengths
    - 12.1.3.4.2 Strategic choices
    - 12.1.3.4.3 Weaknesses and competitive threats
- 12.1.4 LONZA
  - 12.1.4.1 Business overview
  - 12.1.4.2 Products offered
  - 12.1.4.3 Recent developments
    - 12.1.4.3.1 Product launches
  - 12.1.4.4 MnM view
    - 12.1.4.4.1 Key strengths
    - 12.1.4.4.2 Strategic choices
    - 12.1.4.4.3 Weaknesses and competitive threats
- 12.1.5 AVANTOR, INC.
  - 12.1.5.1 Business overview
  - 12.1.5.2 Products offered
- 12.1.6 TECAN TRADING AG
  - 12.1.6.1 Business overview
  - 12.1.6.2 Products offered
  - 12.1.6.3 MnM view
    - 12.1.6.3.1 Key strengths
    - 12.1.6.3.2 Strategic choices
    - 12.1.6.3.3 Weaknesses and competitive threats
- 12.1.7 REPROCELL INC.
  - 12.1.7.1 Business overview
  - 12.1.7.2 Products offered
  - 12.1.7.3 Recent developments
    - 12.1.7.3.1 Deals
- 12.1.8 3D BIOTEK LLC
  - 12.1.8.1 Business overview
  - 12.1.8.2 Products offered
- 12.1.9 EMULATE, INC.
  - 12.1.9.1 Business overview
  - 12.1.9.2 Products offered
  - 12.1.9.3 Recent developments
    - 12.1.9.3.1 Product launches
- 12.1.10 SYNTHECON, INCORPORATED
  - 12.1.10.1 Business overview
  - 12.1.10.2 Products offered
- 12.1.11 INSPHERO
  - 12.1.11.1 Business overview
  - 12.1.11.2 Products offered
  - 12.1.11.3 Recent developments
    - 12.1.11.3.1 Deals
    - 12.1.11.3.2 Other developments
- 12.1.12 KIRKSTALL LTD.
  - 12.1.12.1 Business overview
  - 12.1.12.2 Products offered
- 12.1.13 GREINER BIO-ONE INTERNATIONAL GMBH
  - 12.1.13.1 Business overview
  - 12.1.13.2 Products offered
- 12.1.14 PROMOCELL GMBH
  - 12.1.14.1 Business overview
  - 12.1.14.2 Products offered
- 12.1.15 UPM
  - 12.1.15.1 Business overview
  - 12.1.15.2 Products offered
12.2 OTHER PLAYERS
- 12.2.1 CN BIO INNOVATIONS LTD.
- 12.2.2 TISSUSE GMBH
- 12.2.3 LENA BIOSCIENCES
- 12.2.4 CELLENDES GMBH
- 12.2.5 ADVANCED BIOMATRIX, INC. (PART OF BICO)
- 12.2.6 SYNVIVO, INC.
- 12.2.7 AMS BIOTECHNOLOGY (EUROPE) LTD
- 12.2.8 MIMETAS B.V.
- 12.2.9 S-BIO, VAUPELL HOLDINGS INC.
- 12.2.10 NANOFIBER SOLUTIONS

13 APPENDIX

13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS